Propanc Helping to Unravel Mystery Associated with Carcinomas

MELBOURNE, Australia, March 11, 2015 /PRNewswire/ -- Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced fresh new insights have emerged into the development and spread of carcinomas, published in the British Journal of Cancer by researchers from the University of Glasgow. The findings may have significant implications for Propanc's lead product, PRP, as a new method to control cancer spread, known as metastasis, the main cause of patient death from cancer.

In her article, author Professor Laura Machesky describes how tight controls on cell growth and migration required for maintaining healthy tissues can present problems when normal pathways are disrupted.  Cancers arising from these tissues, called epithelial tissues, covering internal organs and other internal surfaces in the body, are known as carcinomas.  One of the most well-studies features of carcinomas, associated with aggressiveness and 'metastatic spread', is the loss of function of epithelial integrity, called the epithelial to mesenchymal transition, or EMT, when cancer cells become motile and invasive, seeding new tumors.  Whilst only beginning to be fully understood, she concludes the EMT may provide insight that becomes a useful target for treating cancer.

"PRP involves the use of two pancreatic proenzymes, chymotrypsinogen and trypsinogen, which are enzymes in their inactive form.  When administered to a patient, we believe they are activated at the tumor site, altering the cancer cell's signaling pathways and pushing the cells back to normal behavior, so they die naturally," said Dr Julian Kenyon, Propanc's Chief Scientific Officer. "Reversing the EMT process is a key feature of PRP and is fast becoming a credible solution to controlling cancer cell migration," he added.

James Nathanielsz, Propanc's Chief Executive Officer commented, "It is encouraging to see research institutions from around the world focusing their efforts into better understanding the EMT process.  As we unravel the mystery behind how carcinomas develop, our confidence increases regarding the potential for PRP and what it could mean for cancer sufferers around the world."

Propanc Health Group intends to fast track the development of PRP into human trials, initially for colorectal and pancreatic tumors.  The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.6 billion by 2017, according to research reports.

About Propanc:

We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.

In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.

Forward-looking Statements:

Certain of the matters discussed in this announcement involve risks and uncertainties  including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its  technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position.  See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.

SOURCE Propanc Health Group Corporation

Related Links

http://www.propanc.com